In subcutaneous syngeneic murine tumor models, a single intratumoral injection of BI-STING, a CDN mimicking natural STING ligand, resulted in dose-dependent anti-tumor activity and inhibition of tumor development upon re-challenge [77]. The gene discussed is STING1; the disease is neoplasm.